The potential is just terrific imo. The public hea

The potential is just terrific imo. The public health research institute added to the list. The catalysts just keep on building. And we still have the Alfa licensing as well. I'm wondering who is doing the consulting, I doubt Leo is doing it alone. Maybe Locust Walk has a hand in it? I dunno.

But yeah, I've been adding to my IRA and my taxable account. There's been a lockdown on many of the covid bio chasers, we'll see if they have the goods but imo, the way IPIX is progressing we could be well on our way to solid data that proves its worth against the virus. A matter of weeks for the lung data and still waiting to hear something from the university.

Feb 24 Asia
http://www.ipharminc.com/press-release/2020/2...s-covid-19


March 5th P2 trial for UC reviewing CRO's
http://www.ipharminc.com/press-release/2020/3...ve-colitis

March 6 A major U.S. university
http://www.ipharminc.com/press-release/2020/3...-treatment

March 9 Regional Biocontainment Labs (RBLs) in the United States
http://www.ipharminc.com/press-release/2020/3...s-covid-19

May 5th A public health research institute
http://www.ipharminc.com/press-release/2020/5...-institute

A lot going on that's for sure. And MUCH of it on their dime, not ours!


I need to add yours to mine Mo and make a new sticky at the swamp, with your permission of course.

Quote:

---

Posted By: Mo


Tuesday's PR is the 3rd MTA that IPIX has signed to advance Brilacidin as a treatment and possibly as a key adjuvant component for a successful vaccine for COVID-19. The first was with “a leading US based virology lab", the second with the Regional Biocontainment Lab (RBL) that is currently doing human lung cell testing and today the third MTA with “a leading U.S.-based Public Health Research Institute with access to a Biosafety Level-3 (BSL-3) laboratory”. In addition to these 3 MTA avenues, IPIX has also referenced per the 2/24/20 PR that discussions with both an Asian government-backed lab (which I am guessing is not China) and submitted a summary of Brilacidin for CV19 to BARDA. On 3/6/20 The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants. On 4/6/20 IPIX PRed discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials. Any of the above opportunities could lead to advancing Brilacidin’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications.

Details regarding the above initiatives are attached below. Some of this information was included in a prior post of mine.
====================================================

Note that the first MTA was submitted 2/24/20 with "a leading US based virology lab" and also mentions discussions with an Asian government-backed lab (which I am guessing is not China) and submitted a summary of Brilacidin for CV19 to BARDA which is dedicated to rapidly identifying and funding medical countermeasures to the COVID-19 outbreak.”

The first MTA was signed 3 days later with the RBL on 2/27/20.

The second MTA was signed on 3/6/20 with “a major University with one of the world’s leading coronavirus experts overseeing the research”. The PR also stated “The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants to further evaluate and potentially advance Brilacidin’s clinical development as a novel COVID-19 treatment.”

A 3/10/20 “The Company hopes to disclose the RBL’s research agenda for Brilacidin in the coming days. The upcoming research is being funded by third parties independent of Innovation Pharmaceuticals.” (Why would they use the plural “parties”?)

3/17/20 Details of the second MTA that was announced initially on 3/6/20. This is the first discussion of Brilacidin as an adjuvant for a vaccine.

4/1/20 Successful completion of monkey cell testing with IPIX “In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications.”

4/6/20 “Announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic..”

4/27/20 Details of human lung cell testing for direct virucidal activity Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity); “Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”

5/5/20 “The Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19 to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus.”


Read More: https://investorshangout.com/post/newpost/873...z6LfxX8tsY

---